{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:18:45Z","timestamp":1792361925974,"version":"4.4.0"},"reference-count":38,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"11","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest. Ophthalmol. Vis. Sci."],"published-print":{"date-parts":[[2024,9,9]]},"DOI":"10.1167\/iovs.65.11.15","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T11:31:00Z","timestamp":1725881460000},"page":"15","source":"Crossref","is-referenced-by-count":18,"title":["Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab"],"prefix":"10.1167","volume":"65","author":[{"given":"Takahito","family":"Todoroki","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyako","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai Fujita","family":"Sajiki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji M.","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.oret.2019.01.018","article-title":"Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a \u201ctreat-and-extend\u201d regimen","volume":"3","author":"Traine","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10384-020-00783-8","article-title":"Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration","volume":"65","author":"Tsunekawa","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ophtha.2020.06.028","article-title":"HAWK and HARRIER: ninety-six-week outcomes from the Phase 3 trials of brolucizumab for neovascular age-related macular degeneration","volume":"128","author":"Dugel","year":"2021","journal-title":"Ophthalmology"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol Med"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells8050471","article-title":"Role of angiopoietin-2 in vascular physiology and pathophysiology","volume":"8","author":"Akwii","year":"2019","journal-title":"Cells"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin \u00df1 activation","volume":"6","author":"Hakanpaa","year":"2015","journal-title":"Nat Commun"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"10326","key":"bib11","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and Lucerne): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"bib14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ajo.2009.06.012","article-title":"Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration","volume":"148","author":"Ahn","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/j.ophtha.2009.05.039","article-title":"Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab","volume":"116","author":"Funk","year":"2009","journal-title":"Ophthalmology"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/j.ophtha.2012.07.041","article-title":"Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab","volume":"119","author":"Muether","year":"2012","journal-title":"Ophthalmology"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.2147\/OPTH.S171636","article-title":"Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment","volume":"12","author":"Pongsachareonnont","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00417-021-05445-0","article-title":"Cytokine profiles of macular neovascularization in the elderly based on a classification from a pachychoroid\/drusen perspective","volume":"260","author":"Inoda","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12886-021-02152-6","article-title":"Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients","volume":"21","author":"Joo","year":"2021","journal-title":"BMC Ophthalmol"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1167\/iovs.15-16418","article-title":"Intraocular pharmacokinetics of aflibercept and vascular endothelial growth factor-A","volume":"56","author":"Celik","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ceo.13002","article-title":"Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration","volume":"46","author":"Sawada","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"bib22","doi-asserted-by":"publisher","first-page":"a009183","DOI":"10.1101\/cshperspect.a009183","article-title":"Receptor tyrosine kinase-mediated angiogenesis","volume":"5","author":"Jeltsch","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"bib24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00125-006-0539-2","article-title":"Placental growth factor-1 and epithelial haemato-retinal barrier breakdown: potential implication in the pathogenesis of diabetic retinopathy","volume":"50","author":"Miyamoto","year":"2007","journal-title":"Diabetologia"},{"key":"bib25","first-page":"5616","article-title":"Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies","volume":"58","author":"Zhang","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"bib26","doi-asserted-by":"publisher","first-page":"e10204","DOI":"10.15252\/emmm.201810204","article-title":"Efficacy of simultaneous VEGF-A\/ANG-2 neutralization in suppressing spontaneous choroidal neovascularization","volume":"11","author":"Foxton","year":"2019","journal-title":"EMBO Mol Med"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1172\/JCI74527","article-title":"Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature","volume":"124","author":"Shen","year":"2014","journal-title":"J Clin Invest"},{"issue":"6","key":"bib28","doi-asserted-by":"publisher","first-page":"e869","DOI":"10.1111\/aos.14691","article-title":"Systemic counterregulatory response of angiopoietin-2 after aflibercept therapy for nAMD: a potential escape mechanism","volume":"99","author":"Angermann","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.oret.2017.04.004","article-title":"Bevacizumab injection in patients with neovascular age-related macular degeneration increases angiogenic biomarkers","volume":"2","author":"Cabral","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"bib30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/07357907.2015.1088948","article-title":"Angiopoietin-2 may be involved in the resistance to bevacizumab in recurrent glioblastoma","volume":"34","author":"Labussi\u00e8re","year":"2016","journal-title":"Cancer Invest"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.celrep.2014.06.059","article-title":"Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade","volume":"8","author":"Rigamonti","year":"2014","journal-title":"Cell Rep"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/01.MP.0000071841.17900.69","article-title":"Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?","volume":"16","author":"Moon","year":"2003","journal-title":"Mod Pathol"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1620\/tjem.213.33","article-title":"Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma","volume":"213","author":"Wang","year":"2007","journal-title":"Tohoku J Exp Med"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/OPTH.S395279","article-title":"Intravitreal faricimab for aflibercept-resistant neovascular age-related macular degeneration","volume":"16","author":"Rush","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/jcm12155145","article-title":"Short-term outcomes of faricimab treatment in aflibercept-refractory eyes with neovascular age-related macular degeneration","volume":"12","author":"Kishi","year":"2023","journal-title":"J Clin Med"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1007\/s40123-023-00779-w","article-title":"Visual and anatomical outcomes after initial intravitreal faricimab injection for neovascular age-related macular degeneration in patients with prior treatment history","volume":"12","author":"Inoda","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.ophtha.2009.04.017","article-title":"Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study","volume":"116","author":"Yasuda","year":"2009","journal-title":"Ophthalmology"}],"container-title":["Investigative Ophthalmology & Visual Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2800787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:31:47Z","timestamp":1791927107000},"score":1,"resource":{"primary":{"URL":"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2800787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1167\/iovs.65.11.15","relation":{},"ISSN":["1552-5783"],"issn-type":[{"value":"1552-5783","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}